Epizyme Story

EPZMDelisted Stock  USD 1.47  0.00  0.00%   
About 56% of Epizyme's investor base is looking to short. The analysis of current outlook of investing in Epizyme suggests that many traders are alarmed regarding Epizyme's prospects. Epizyme's investor sentiment overview provides quick insight into current market opportunities from investing in Epizyme. The current market sentiment, together with Epizyme's historical and current headlines, can help investors time the market. In addition, many technical investors use Epizyme stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Epizyme stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Epizyme daily returns and investor perception about the current price of Epizyme as well as its diversification or hedging effects on your existing portfolios.
  

Requested story not found. it has been either deleted or moved. View all stories for Epizyme.

Epizyme Latest Timeline

Epizyme is listed for 1.47. About 90.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.0. Some equities with similar Price to Book (P/B) outperform the market in the long run. Epizyme recorded a loss per share of 2.3. The entity had not issued any dividends in recent years.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the Epizyme information on this page should be used as a complementary analysis to other Epizyme's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Consideration for investing in Epizyme Stock

If you are still planning to invest in Epizyme check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Epizyme's history and understand the potential risks before investing.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Global Correlations
Find global opportunities by holding instruments from different markets
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Fundamental Analysis
View fundamental data based on most recent published financial statements
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Equity Valuation
Check real value of public entities based on technical and fundamental data